

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

January 11, 1999

000-27078

Date of Report (Date of earliest
event reported)

(Commission File Number)

HENRY SCHEIN, INC.
(Exact name of registrant as specified in its charter)

Delaware

11-3136595

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer Identification Number)

135 Duryea Road, Melville, NY 11747

(Address of Principal Executive Offices) (Zip Code)

(516) 843-5500

(Registrant's telephone number, including area code)

ITEM 5. OTHER EVENTS.

On January 12, 1999, Henry Schein, Inc. issued the press release filed as an Exhibit to this Current Report on Form 8-K with respect to the receipt by its unconsolidated affiliate, Novocol Pharmaceutical of Canada, Limited, of a warning letter from the United States Food and Drug Administration regarding Novocol's compliance with current good manufacturing practices with respect to its dental anesthetic products. The press release describes, among other things, the voluntary action being taken by Novocol in connection with the warning letter.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

(a) Not applicable.

(b) Not applicable.

(c) Exhibits:

99. Press Release, dated January 11, 1999.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, Henry Schein, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HENRY SCHEIN, INC.

By: /s/ Michael Ettinger

Name: Michael Ettinger
Title: Vice President and Associate
General Counsel

Date: January 11, 1999

EXHIBIT INDEX

DOC.	NO. DOCUMENT DESCRIPTION
99	Press Release, dated January 11, 1999.

[Henry Schein Letterhead]

FOR: Henry Schein, Inc.
CONTACT: Steven Paladino
Senior Vice President and
Chief Financial Officer
(516) 843-5500

Susan Vassallo
Manager, Investor
and Public Relations
(516) 843-5562
svassa@henryschein.com

FOR IMMEDIATE RELEASE

Investor Relations:
Robert P. Jones/Jill Ruja
Press: Stacy Berns
Morgen-Walke Associates
(212) 850-5600

HENRY SCHEIN, INC. AFFILIATE RESPONDS TO U.S. FDA

Melville, NY -- January 11, 1999 -- Henry Schein, Inc. (Nasdaq:HSIC) announced today that Novocol Pharmaceutical of Canada, Ltd., (Novocol), an affiliated company in which it owns a non-controlling interest, has received a Warning Letter from the United States Food and Drug Administration (FDA) regarding Novocol's compliance with current Good Manufacturing Practices (cGMP's) of its dental anesthetic products. Henry Schein's equity in earnings of this unconsolidated affiliate is estimated at \$1.6 million for 1998. In addition, these products represented \$15 million of Henry Schein's estimated 1998 sales.

In cooperation with the FDA, Novocol is conducting a voluntary recall of certain product batches and has temporarily suspended shipping these products to the United States. Additionally, at the request of the FDA, Novocol is reviewing all protocols and policies regarding the manufacturing of the anesthetic products and is working closely with the FDA to resolve these issues as quickly as possible. However, Novocol is unable at this time to estimate how long it will take to resolve these issues with the FDA.

Henry Schein, Inc. is the largest distributor of healthcare products and services to officebased healthcare practitioners, including dental practices and laboratories, physician practices and veterinary clinics. The Company, recognized for its excellent customer service and low prices, serves more than 250,000 customers worldwide. Henry Schein's world headquarters are in Melville, N.Y. For more information, visit the Henry Schein website at <http://www.henryschein.com>.

Certain information contained herein includes information that is forward looking. The matters referred to in forward looking statements may be affected by the risks and uncertainties involved in the Company's business. These forward looking statements are qualified in their entirety by the cautionary statements contained in the Company's Securities and Exchange Commission filings.

###